A recent study reported that a shared neoantigen, tumor protein 53, in which arginine is replaced with histidine at position 175 (p53R175H), can be targeted by a highly specific TCR-mimic antibody that is HLA-A*0201-restricted p53R175H and can lyse tumor cells expressing the neoantigen [51]. This evidence concerns the gene TP53 and neoplasm.